Skip to main content
. 2020 Jan 28;8(1):e000492. doi: 10.1136/jitc-2019-000492

Figure 3.

Figure 3

PFS (A) and OS according to immunotherapy agent in two trials of stereotactic body radiation therapy given with either anti-CTLA4 or anti-PD1 for metastatic non-small cell lung cancer. CTLA4, cytotoxic T-lymphocyte-associated protein 4; OS, overall survival; PD1, programmed death-1; PFS, progression-free survival.